Literature DB >> 3133573

Effect of L-threo-3,4-dihydroxyphenylserine on muscle sympathetic nerve activities in Shy-Drager syndrome.

T Kachi1, S Iwase, T Mano, M Saito, M Kunimoto, I Sobue.   

Abstract

We observed changes in postganglionic efferent discharges of muscle sympathetic nerve (muscle sympathetic activity, MSA) microneurographically before and after the oral administration of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS), a precursor of norepinephrine, in a patient with Shy-Drager syndrome and irregular fluctuations of blood pressure. Before drug administration, MSA was only rarely observed with the patient in the supine position. There was a slight increase in MSA during head-up tilting to 40 degrees, and orthostatic hypotension (OH) occurred just after the body was tilted head upward to 40 degrees. MSA became prominent 30 minutes after the oral administration of 200 mg of L-threo-DOPS while the patient was in a 40 degree head-up position, and the OH was improved. The MSA discharge rate decreased and OH reappeared 3 hours after oral administration, when the plasma concentration of norepinephrine was at its highest level. We suggest that the OH improved mainly because of the increase in MSA due to L-threo-DOPS, and that the drug may activate sympathetic outflow at a site proximal to the sympathetic ganglion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133573     DOI: 10.1212/wnl.38.7.1091

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

Review 1.  Otoneurological manifestations of the Shy-Drager syndrome.

Authors:  N Ohashi; H Nakagawa; K Kanda; K Mizukoshi
Journal:  Eur Arch Otorhinolaryngol       Date:  1991       Impact factor: 2.503

2.  Epidemiology, Diagnosis, and Management of Neurogenic Orthostatic Hypotension.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Mov Disord Clin Pract       Date:  2017-03-16

3.  The effects of the noradrenaline precursor, L-threo-3,4-dihydroxyphenylserine, in children with orthostatic intolerance.

Authors:  H Tanaka; H Yamaguchi; M Mino
Journal:  Clin Auton Res       Date:  1996-08       Impact factor: 4.435

4.  Vasomotor regulation in patients with multiple system atrophy.

Authors:  Kazumasa Shindo; Mai Tsuchiya; Yuta Ichinose; Kishin Koh; Takanori Hata; Nobuo Yamashiro; Fumikazu Kobayashi; Takamura Nagasaka; Yoshihisa Takiyama
Journal:  J Neural Transm (Vienna)       Date:  2016-11-08       Impact factor: 3.575

5.  Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?

Authors:  Horacio Kaufmann
Journal:  Clin Auton Res       Date:  2017-06-16       Impact factor: 4.435

6.  L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.

Authors:  C J Mathias; J M Senard; S Braune; L Watson; A Aragishi; J E Keeling; M D Taylor
Journal:  Clin Auton Res       Date:  2001-08       Impact factor: 4.435

7.  Microneurographic analysis of muscle sympathetic nerve activity in amyotrophic lateral sclerosis.

Authors:  K Shindo; S Tsunoda; Z Shiozawa
Journal:  Clin Auton Res       Date:  1993-04       Impact factor: 4.435

8.  Acute pandysautonomia: mass spectrometric and histopathological studies of the sympathetic nervous system during long term L-threo-3,4-dihydroxyphenylserine treatment.

Authors:  M Ushiyama; S Ikeda; T Suzuki; M Yazawa; N Yanagisawa; S Tsujino
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

9.  Droxidopa in neurogenic orthostatic hypotension.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-06-19

10.  Shy-Drager syndrome. Effect of fludrocortisone and L-threo-3,4-dihydroxyphenylserine on the blood pressure and regional cerebral blood flow.

Authors:  S Matsubara; Y Sawa; H Yokoji; M Takamori
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.